Skip to content

Natural History Study in Inherited Retinal Disease Subjects Caused by Mutations in RPE65 or LRAT

Retrospective, Uncontrolled, Multicenter, Case History Study to Determine the Natural History of Visual Function in Subjects With Inherited Retinal Disease (IRD) Caused by Inherited Mutation of Retinal Pigment Epithelial 65 Protein (RPE65) or Lecithin:Retinol Acyltransferase (LRAT)

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02575430
Enrollment
59
Registered
2015-10-14
Start date
2015-12-31
Completion date
2016-03-31
Last updated
2016-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Leber Congenital Amaurosis (LCA), Retinitis Pigmentosa (RP)

Brief summary

To evaluate the natural history of visual function in subjects with IRD phenotypically diagnosed as Leber congenital amaurosis (LCA) or retinitis pigmentosa (RP) caused by RPE65 or LRAT gene mutations.

Detailed description

This is a retrospective, uncontrolled, multicenter, case history study to determine the natural history of visual function in patients with IRD phenotypically diagnosed as LCA or RP caused by autosomal recessive mutation in RPE65 or LRAT. Up to 60 subjects will be enrolled in this study at approximately 12 study centers in Canada, the US and Europe.

Interventions

OTHERNo treatment: retrospective chart review

Sponsors

QLT Inc.
Lead SponsorINDUSTRY

Study design

Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
8 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Male or female subjects aged 8 or older with IRD (LCA or RP) caused by inherited autosomal recessive mutation in either RPE65 or LRAT. * Subjects who have at least 2 documented kinetic visual field assessments of the same isopter(s) in at least one eye performed at least 2 years apart on the same type of equipment when the subject was between the ages of 6 and 65 years. * If applicable, subjects who provide informed consent for the study (the requirement for informed consent may be applicable to all sites or may be waived by the IRB and/or local regulations). The parent or guardian must sign an approved informed consent form for the study for subjects younger than the age of majority.

Exclusion criteria

* Subjects, who in the Investigator's opinion, have any severe acute or chronic medical condition, psychiatric condition, physical examination finding or laboratory abnormality that may interfere with the interpretation of their visual function data. * Subjects with concomitant bilateral ocular disorders that may affect visual acuity or visual fields (e.g., advanced glaucoma, optic neuritis, anterior ischemic optic neuropathy, advanced cataract, intraocular surgery).

Design outcomes

Primary

MeasureTime frame
Visual fieldChange in visual field over time. Previous assessments performed when subject was between the ages of 6 and 65 years

Secondary

MeasureTime frame
Visual acuityChange in visual acuity over time. Previous assessments performed when subject was between the ages of 6 and 65 years

Other

MeasureTime frame
Optical coherence tomography, if availablePrevious assessments performed when subject was between the ages of 6 and 65 years
Electroretinogram, if availablePrevious assessments performed when subject was between the ages of 6 and 65 years

Countries

Canada, Denmark, Germany, Netherlands, Switzerland, United Kingdom, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026